Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood

Phase 2

Suspended

Brief Summary: This is a single-center, Phase II study including only patients on whom a decision to conduct radiofrequency ablation (RFA) has already been made. The primary objective of this study assess if quality of life was improved by RFA as assessed at baseline, 3 and potentially 6 and 12 months following RFA for the benign lesions.

RFA is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using an electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.

RF ablation is an alternative for local tumor control when other treatments (surgery, radiotherapy or chemotherapy) are not feasible (less effective or at higher risk). Thermal ablation at times is the only remaining alternative for patient cure, prolonged survival or palliation. Cryotherapy, and microwave, laser and focused ultrasound are alternative thermal ablation techniques used in adults but there has been no experience in children with these alternative methods.

To be eligible for this study, patients must have acquired lesions at \< 21 years of age (central nervous system lesions are excluded from this study). Study participants will have the RFA procedure performed at Seattle Children's and will have follow-up evaluations at various time points post-RFA.

Recruitment & Eligibility

Inclusion Criteria

Lesion acquired in childhood (at <21 years of age)
Any lesion location except CNS
Any malignant tumor or metastasis
Any benign lesion (e.g. desmoids, venous or lymphatic vascular anomalies, aneurysmal bone cysts, osteoid osteoma, tongue hypertrophy, or painful neuropathy)
Patients with malignant disease have had histologic confirmation of disease at initial diagnosis.
≥ 90 day life expectancy
Potential benefit of RFA outweighs risk as determined by PI
Other local tumor control measures are not recommended for malignant lesion based on review in multidisciplinary team conference or the patient refuses recommended local tumor control measures
The patient is not expected to become short of breath at rest after RFA (forced vital capacity ≥33% of normal by pulmonary function tests) if pulmonary RFA is considered

Exclusion Criteria

Patients with uncontrolled infection.
Patients with co-morbidities affecting inclusion criteria above.
Patients who are pregnant and/or breastfeeding.
Patients who had a change in chemotherapy within one month before RFA
Patients who have planned change in chemotherapy and/or radiation therapy (to same site as RFA) interventions within the first three months following RFA.
Patients should not be considered for pulmonary RFA if they have poorly compliant lungs (recently required mechanical ventilation) or require supplemental oxygen.

Arm && Interventions

Group	Intervention	Description
Radiofrequency Ablation	Radiofrequency ablation (RFA)	-

Primary Outcome Measures

Name	Time	Method
Assess if quality of life was improved by RFA for the benign lesions	baseline, 3 months and potentially 6 and 12 months following RFA

Secondary Outcome Measures

Name	Time	Method
Assess the response to RF ablative therapy by pain relief from painful benign or malignant lesions.	baseline, 3 months and potentially 6 and 12 months following RFA
Evaluate the rate of short-term ablation of benign lesions produced by RFA	baseline, 3 months and potentially 6 and 12 months following RFA
Assess toxicity related to all RFA procedures using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0	within 3 months (potentially 6-12 months) following RFA
Assess the response to RFA by malignant tumor markers (e.g. AFP)	1, 3, 6, and 12 months following RFA
Assess if quality of life was improved by RFA for patients with malignant lesions	baseline, 3, 6 and 12 months
Evaluate the proportion of malignant lesions that show short-term ablation produced by RFA.	3 months post Radiofrequency Ablation (RFA), as compared to 1 month post RFA imaging
Determine the rate of durable ablation in malignant lesions that achieve short-term ablation by RFA	12 months post RFA
Assess the time to malignant tumor progression (as defined by RECIST) of lesions treated with RFA	1, 3, 6, and 12 months post RFA

Locations (1): Seattle Children's Hospital
🇺🇸
Seattle, Washington, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial